Development of AAV Therapeutics
Posted on 04/12/2018
On Wednesday 30th January 2019, KTN in partnership with MedImmune will be co-hosting a meeting on the Development of AAV Therapeutics, taking place at the Milstein Building at MedImmune in Cambridge. This meeting will bring together professionals from industry and academia to disseminate and share information on the development of adeno-associated virus therapeutics (AAV), specifically focussing on the manufacturing focus and highlighting the areas of need for this community.
This event is timely given the increased recognition of AAV therapeutics in recent years. For instance, last year’s FDA approval for Spark Therapeutics’ Luxturna™ for inherited retinal disease marked the first approval for an AAV-based therapy in the USA. This followed on from European approval AAV therapeutic Glybera® (UniQure) in 2012 for the treatment of ultra-rare hereditary lipoprotein lipase deficiency, but this was subsequently withdrawn due to the lack of commercial success. Nevertheless, the marketing approvals of these therapeutics shows the increasing maturity of AAV-based therapeutics. Furthermore, the UK has a strong presence in the research and development of AAV therapeutics. This increasing R&D into AAV therapeutics in turn leads to greater regulatory success.
The event will host oral presentations as well as the opportunity to present posters. There will also be the opportunity for 1-2-1 meetings during networking sessions, to maximise the opportunity for future collaborations.
For more information please contact Marcel Kuiper.
To register your attendance please click here.